scholarly journals Enhanced differentiation of human dopaminergic neuronal cell model for preclinical translational research in Parkinson's disease

Author(s):  
Dilshan S. Harischandra ◽  
Dharmin Rokad ◽  
Shivani Ghaisas ◽  
Saurabh Verma ◽  
Alan Robertson ◽  
...  
2009 ◽  
Vol 108 (6) ◽  
pp. 1561-1574 ◽  
Author(s):  
Roberta Marongiu ◽  
Brian Spencer ◽  
Leslie Crews ◽  
Anthony Adame ◽  
Christina Patrick ◽  
...  

Molecules ◽  
2021 ◽  
Vol 26 (11) ◽  
pp. 3329
Author(s):  
Yeon Joo Choi ◽  
Dae Won Kim ◽  
Min Jea Shin ◽  
Hyeon Ji Yeo ◽  
Eun Ji Yeo ◽  
...  

Parkinson’s disease (PD) is characterized mainly by the loss of dopaminergic neurons in the substantia nigra (SN) mediated via oxidative stress. Although glutaredoxin-1 (GLRX1) is known as one of the antioxidants involved in cell survival, the effects of GLRX1 on PD are still unclear. In this study, we investigated whether cell-permeable PEP-1-GLRX1 inhibits dopaminergic neuronal cell death induced by 1-methyl-4-phenylpyridinium (MPP+) and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). We showed that PEP-1-GLRX1 protects cell death and DNA damage in MPP+-exposed SH-SY5Y cells via the inhibition of MAPK, Akt, and NF-κB activation and the regulation of apoptosis-related protein expression. Furthermore, we found that PEP-1-GLRX1 was delivered to the SN via the blood–brain barrier (BBB) and reduced the loss of dopaminergic neurons in the MPTP-induced PD model. These results indicate that PEP-1-GLRX1 markedly inhibited the loss of dopaminergic neurons in MPP+- and MPTP-induced cytotoxicity, suggesting that this fusion protein may represent a novel therapeutic agent against PD.


2014 ◽  
Vol 55 (3) ◽  
pp. 803-811 ◽  
Author(s):  
Keisuke Kiriyama ◽  
Hirokazu Ohtaki ◽  
Natsuki Kobayashi ◽  
Norimitsu Murai ◽  
Minako Matsumoto ◽  
...  

2021 ◽  
Author(s):  
Wenyong Ding ◽  
Minghua Qi ◽  
Li Ma ◽  
Xuefei Xu ◽  
Yingfei Chen ◽  
...  

Abstract Background: ADP/ATP translocase 1 (ANT1) is involved in the exchange of cytosolic ADP and mitochondrial ATP, and its defection plays an important role in mitochondrial pathogenesis. To reveal an etiological implication of ANT1 for Parkinson’s disease (PD), a neurodegenerative disorder, a mouse model treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine and neuroblasma cell model induced by 1-methyl-4-pehny1-pyridine were utilized in this study. Results: The tissue-specific abundance in ANT1 in mouse brains was accessed using the analysis of Western blot and immunohistochemistry. Down-regulated soluble ANT1 was found to be correlated with PD, and ANT1 was associated with PD pathogenesis via forming protein aggregates with α-synuclein. This finding was confirmed at cellular level using neuroblasma cell models. Protein interaction assay, coupled with the analysis of LC-MS/MS, silver-stained SDS-PAGE and Western blot against anti-ANT1 antibody respectively, illustrated the interaction of ANT1 with α-synuclein using the expressed α-synuclein as a bite. Additionally, a significant increasing ROSs was detected in PD-like cells. Conclusions: his study indicated that ANT1 was a potentially causative factor of PD, and led to neuropathogenic injury via promoting the formation of protein aggregates with α-synuclein. This investigation potentially promotes an innovative understanding of ANT1 on the etiology of PD and provides valuable information on developing potential drug targets in PD treatment or reliable biomarkers in PD prognostication.


Sign in / Sign up

Export Citation Format

Share Document